Vendor, New York, NY
Nomocan Pharmaceuticals LLC
UEI H9T8M7ZBYAR8, CAGE 7ER28
1 award and $0 obligated between September 1, 2026 and September 1, 2026, 100% under full and open competition, against 16.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $0 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N91025C00050Definitive Contract, September 1, 2026, Full and Open Competition After Exclusion of Sources, 16 offers | NIH NCINational Institutes of Health | Eo 14398; Nomocan Phase I - Development of Therapeutic or Preventative Technologies for Treatment or Prevention of Pediatric Cancers And/Or NAICS 541715, PSC AN12 | $0 |
- Places of performance
- New York
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 1 across 1 awards